Roeber Florian, Jackson Chrissie, Chambers Michael, Smith Veronica, Hume Jane, Blazejak Katrin, Mencke Norbert
Invetus Pty Ltd., Wongaburra Research Centre, Casino, NSW, 2470, Australia.
Animal Ethics Pty Ltd., 363 Steeles Road, Yarra Glen, VIC, 3775, Australia.
Curr Res Parasitol Vector Borne Dis. 2023 May 30;4:100123. doi: 10.1016/j.crpvbd.2023.100123. eCollection 2023.
The Australian paralysis tick continues to be a serious threat to companion animals along Australia's east coast. The tick produces a potent neurotoxin which causes a rapidly ascending flaccid paralysis, which if left untreated, can result in the death of the animal. There is currently only a limited number of products registered in Australia for the treatment and control of paralysis ticks in cats. Felpreva® is an effective spot-on combination containing emodepside, praziquantel and tigolaner. To investigate the therapeutic and long-term persistent efficacy of Felpreva® (2.04% w/v emodepside, 8.14% w/v praziquantel and 9.79% w/v tigolaner) against experimental infestation with in cats, two studies were undertaken. Fifty cats were included in the studies on study Day -17. These cats were immunized against paralysis tick holocyclotoxin prior to the study commencing. Immunity to holocyclotoxin was confirmed with a tick carrying capacity (TCC) test conducted prior to treatment. Cats were treated once on Day 0. Group 1 cats were treated with the placebo formulation and Group 2 cats were treated with Felpreva®. Cats were infested on Days -14 (tick carrying capacity test), 0, 28, 56, 70, 84 and 91 (weeks 4, 8, 10, 12 and 13). Ticks were counted on cats 24 h, 48 h and 72 h post-treatment and infestation, except during the tick carrying capacity test when they were counted approximately 72 h post-infestation only. The 24-h and 48-h assessments were conducted without removing the ticks. The ticks were assessed, removed and discarded at the 72-h assessment time-points. Significant differences in total live tick counts at ∼24 h, ∼48 h and ∼72 h post-infestation were observed between the treatment and control group. Differences were significant ( < 0.05 to < 0.001) in all instances. Treatment efficacies of 98.1-100% were observed ∼72 h post-infestation through to 13 weeks (94 days) post-treatment. These results show that a single application of Felpreva® provides effective treatment and control against induced infestation with paralysis ticks for 13 weeks.
澳大利亚麻痹蜱仍然是澳大利亚东海岸伴侣动物面临的严重威胁。这种蜱会产生一种强效神经毒素，可导致快速上行性弛缓性麻痹，若不治疗，可能导致动物死亡。目前在澳大利亚仅有数量有限的产品注册用于治疗和控制猫身上的麻痹蜱。福来恩（Felpreva®）是一种有效的滴剂组合，含有埃玛菌素、吡喹酮和替诺拉酯。为研究福来恩（Felpreva®，含2.04% w/v埃玛菌素、8.14% w/v吡喹酮和9.79% w/v替诺拉酯）对猫实验性感染[此处原文缺失具体感染物]的治疗效果及长期持续疗效，开展了两项研究。在研究第 -17天纳入了50只猫。这些猫在研究开始前接种了针对麻痹蜱全环毒素的疫苗。在治疗前通过蜱携带能力（TCC）试验确认了对全环毒素的免疫力。猫在第0天接受一次治疗。第1组猫接受安慰剂制剂治疗，第2组猫接受福来恩（Felpreva®）治疗。猫在第 -14天（蜱携带能力试验）、第0天、第28天、第56天、第70天、第84天和第91天（第4、8、10、12和13周）感染。在治疗和感染后24小时、48小时和72小时对猫身上的蜱进行计数，但在蜱携带能力试验期间，仅在感染后约72小时进行计数。24小时和48小时的评估在不摘除蜱的情况下进行。在72小时评估时间点对蜱进行评估、摘除并丢弃。在感染后约24小时、约48小时和约72小时，治疗组和对照组之间的存活蜱总数存在显著差异。在所有情况下差异均具有显著性（P<0.05至P<0.001）。在感染后约72小时至治疗后13周（94天）观察到治疗效果为98.1% - 100%。这些结果表明，单次使用福来恩（Felpreva®）可有效治疗和控制猫因诱导感染麻痹蜱长达13周。
